- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT06028022
Extrakt z houby Reishi pro únavu a/nebo artralgie/myalgie u pacientů s rakovinou prsu na inhibitorech aromatázy
Extrakt z houby Reishi pro únavu a/nebo artralgii u pacientů s rakovinou prsu na inhibitorech aromatázy: Randomizovaná studie fáze II MNCCTN
This phase II trial tests how well Reishi mushroom extract works in treating fatigue and/or joint/muscle pain (arthralgias/myalgias) in patients with breast cancer on aromatase inhibitors. Fatigue and arthralgias/myalgias are common symptoms in breast cancer patients taking aromatase inhibitors (AI). Given the long duration of AI treatment for some women (up to 10 years), these symptoms can significantly impact quality of life and premature discontinuation of AIs, a beneficial medication. Reishi mushrooms are among several medicinal mushrooms that have been used for hundreds of years, mainly in Asian countries, to help enhance the immune system, reduce stress, improve sleep, and lessen fatigue. Reishi mushroom extracts have not been studied explicitly for treatment-induced arthralgias/myalgias, but have been shown to improve quality of life, muscular strength, pain, and flexibility. Information from this study may help researchers determine the effect of Reishi mushroom extract on fatigue and arthralgias/myalgias in breast cancer patients receiving an AI.
Přehled studie
Postavení
Detailní popis
PRIMARY OBJECTIVE:
I. To evaluate the efficacy of 1,000 mg three times daily (TID) of Reishi mushroom extracts as therapy for cancer-related fatigue measured by uniscale measurement at the end of four weeks.
SECONDARY OBJECTIVES:
I. To evaluate the efficacy of Reishi mushroom extracts as therapy for cancer-related arthralgias at the end of four weeks and four weeks after cross-over as measured by the Brief Pain index (BPI)-adapted for AI associated arthralgias.
II. To evaluate the effect of Reishi mushroom extracts on cancer-related quality of life (QOL), as measured by uniscale, at the end of four weeks and four weeks after cross-over.
III. To evaluate the efficacy of Reishi mushroom extracts on mood, as assessed by the World Health Organization Five Well-Being Index (WHO-5) item well-being scale, at the end of four weeks and four weeks after cross-over.
IV. To evaluate treatment toxicity between the two treatment arms, as measured by a patient symptom experience diary and weekly calls from the study team.
V. To evaluate the interest, knowledge, and acceptance of integrative treatments for cancer-related symptoms.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive Reishi mushroom extract orally (PO) TID on days 1-28 for weeks 1-4 and then placebo PO TID on days 1-28 for weeks 5-8 in the absence of disease progression or unacceptable toxicity.
ARM II: Patients receive placebo PO TID on days 1-28 for weeks 1-4 and Reishi mushroom extract PO TID on days 1-28 for weeks 5-8 in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 30 days.
Typ studie
Zápis (Odhadovaný)
Fáze
- Fáze 2
Kontakty a umístění
Studijní kontakt
- Jméno: Clinical Trials Referral Office
- Telefonní číslo: 855-776-0015
- E-mail: mayocliniccancerstudies@mayo.edu
Studijní místa
-
-
Minnesota
-
Albert Lea, Minnesota, Spojené státy, 56007
- Aktivní, ne nábor
- Mayo Clinic Health System in Albert Lea
-
Baxter, Minnesota, Spojené státy, 56425
- Aktivní, ne nábor
- Essentia Health Baxter Clinic
-
Bemidji, Minnesota, Spojené státy, 56601
- Aktivní, ne nábor
- Sanford Joe Lueken Cancer Center
-
Brainerd, Minnesota, Spojené státy, 56401
- Aktivní, ne nábor
- Essentia Health Saint Joseph's Medical Center
-
Deer River, Minnesota, Spojené státy, 56636
- Aktivní, ne nábor
- Essentia Health Deer River Clinic
-
Detroit Lakes, Minnesota, Spojené státy, 56501
- Aktivní, ne nábor
- Essentia Health Saint Mary's - Detroit Lakes Clinic
-
Duluth, Minnesota, Spojené státy, 55805
- Aktivní, ne nábor
- Essentia Health Cancer Center
-
Ely, Minnesota, Spojené státy, 55731
- Aktivní, ne nábor
- Essentia Health Ely Clinic
-
Fosston, Minnesota, Spojené státy, 56542
- Aktivní, ne nábor
- Essentia Health Fosston
-
Grand Rapids, Minnesota, Spojené státy, 55744
- Aktivní, ne nábor
- Fairview Grand Itasca Clinic & Hospital
-
Hibbing, Minnesota, Spojené státy, 55746
- Aktivní, ne nábor
- Essentia Health Hibbing Clinic
-
Hibbing, Minnesota, Spojené státy, 55746
- Aktivní, ne nábor
- Fairview Range Medical Center
-
International Falls, Minnesota, Spojené státy, 56649
- Aktivní, ne nábor
- Essentia Health International Falls Clinic
-
Mankato, Minnesota, Spojené státy, 56001
- Aktivní, ne nábor
- Mayo Clinic Health Systems-Mankato
-
Monticello, Minnesota, Spojené státy, 55362
- Staženo
- MMCORC CentraCare Monticello Cancer Center
-
Moose Lake, Minnesota, Spojené státy, 55767
- Aktivní, ne nábor
- Essentia Health Moose Lake
-
Park Rapids, Minnesota, Spojené státy, 56470
- Aktivní, ne nábor
- Essentia Health Park Rapids
-
Princeton, Minnesota, Spojené státy, 55731
- Aktivní, ne nábor
- Fairview Northland Medical Center
-
Rochester, Minnesota, Spojené státy, 55905
- Nábor
- Mayo Clinic in Rochester
-
Vrchní vyšetřovatel:
- Stacy D. D'Andre, M.D.
-
Kontakt:
- Clinical Trials Referral Office
- Telefonní číslo: 855-776-0015
- E-mail: mayocliniccancerstudies@mayo.edu
-
Sandstone, Minnesota, Spojené státy, 55072
- Aktivní, ne nábor
- Essentia Health Sandstone
-
Thief River Falls, Minnesota, Spojené státy, 56701
- Aktivní, ne nábor
- Sanford Thief River Falls Medical Center
-
Virginia, Minnesota, Spojené státy, 55792
- Aktivní, ne nábor
- Essentia Health Virginia Clinic
-
Worthington, Minnesota, Spojené státy, 56187
- Aktivní, ne nábor
- Sanford Worthington Medical Center
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Age ≥ 18 years
- History of breast cancer, estrogen receptor positive (ER+), Her 2 positive or negative
- Fatigue ≥ 4/10
- Currently post-menopausal (as defined by National Comprehensive Cancer Network (version 4.2024), taking any aromatase inhibitor in the curative setting and planning to be on such for at least 8 weeks after registration. [Patients on concurrent ovarian suppression (such as with leuprolide acetate, goserelin) are allowed]; CDK 4/6 inhibitors abemaciclib, ribociclib ARE allowed
- Prior treatment: last chemotherapy ≥ 90 days prior to randomization (if treated with chemotherapy)
- On a stable dose of pain medications if pain medications are being regularly used. (i.e., no change in dosage in the past 30 days)
- If on supplements, must be on stable dose with no plan to change; not on or planning any acupuncture or other specific supportive modalities for fatigue or AI arthralgias
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2
- White blood cell count (WBC) ≥ 3,000/mm^3 (obtained ≤ 30 days prior to randomization)
- Hemoglobin ≥ 10 g/dL (obtained ≤ 30 days prior to randomization)
- Platelet count ≥ 100,000/mm^3 (obtained ≤ 30 days prior to randomization)
- Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (obtained ≤ 30 days prior to randomization)
- Alanine aminotransferase (ALT) or aspartate transaminase (AST) ≤ 1.2 x ULN (obtained ≤ 30 days prior to randomization)
- Prothrombin time (PT)/activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN (obtained ≤ 30 days prior to randomization)
- Negative pregnancy test done ≤ 7 days prior to registration, for persons on concurrent ovarian suppression only
- Provide informed consent
- Ability to complete questionnaires
- Willing to return to enrolling institution during the active monitoring phase of the study
- Patients who have had a recent surgery or procedure should be healed and cleared by their clinician and/or surgeon per local standards, prior to registration
Exclusion Criteria:
-
Other known uncontrolled medical conditions causing fatigue such as untreated thyroid disease, depression, fibromyalgia, chronic fatigue syndrome, infection, autoimmune disease, or active/untreated hepatitis
-
Allergy to mushrooms
-
On anticoagulation medication or aspirin or having a known bleeding disorder
-
On any specific medication for fatigue (e.g., methylphenidate)
-
Metastatic cancer diagnosis (history of nodal metastases is allowed)
-
Chronic steroid use, unless on physiologic replacement doses
-
Current use of any medical mushrooms
-
On medications for diabetes
-
History of symptomatic hypotension
-
Taking CYP3A4, CYP2D6 sensitive substrates which can be located at the following link: https://www.fda.gov/drugs/drug-interactions-labeling/healthcare-professionals-fdas-examples-drugs-interact-cyp-enzymes-and-transporter-systems
-
Drugs which exhibit either >20% inhibition or >20% induction of CYP2E1 in vivo, such as: Acetaminophen, Dapsone, Enflurane, Halothane, Isoflurane, & Theophylline
-
Taking olaparib
-
Any of the following because this study involves an agent that has unknown genotoxic, mutagenic and teratogenic effects:
- Pregnant persons
- Nursing persons
- Persons on concurrent ovarian suppression who are unwilling to employ adequate contraception (e.g., hormonal methods, barrier methods, intrauterine device, abstinence)
-
Planned surgery or procedure during time on study and ≤ 14 days after last dose, due to bleeding risks
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Podpůrná péče
- Přidělení: Randomizované
- Intervenční model: Crossover Assignment
- Maskování: Dvojnásobek
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Arm I (Reishi mushroom extract, placebo)
Patients receive Reishi mushroom extract PO TID on days 1-28 for weeks 1-4 and then placebo PO TID on days 1-28 for weeks 5-8 in the absence of disease progression or unacceptable toxicity. |
Ancillary studies
Ostatní jména:
Ancillary studies Given PO Given Reishi mushroom extract PO
Ostatní jména:
|
|
Experimentální: Arm II (placebo, Reishi mushroom extract)
Patients receive placebo PO TID on days 1-28 for weeks 1-4 and Reishi mushroom extract PO TID on days 1-28 for weeks 5-8 in the absence of disease progression or unacceptable toxicity. |
Ancillary studies
Ostatní jména:
Ancillary studies Given PO Given Reishi mushroom extract PO
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Change in fatigue scores
Časové okno: Baseline to end of four weeks
|
Based on a single item fatigue uniscale question. Will be compared between arms using a two-sided two-sample t-test assuming equal variances in each group. |
Baseline to end of four weeks
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Change in quality of life
Časové okno: Baseline to the end of four weeks and four weeks after cross-over
|
Measured by the World Health Organization-Five Well-Being Index. Will be compared between arms using two-sample, two-sided t-tests assuming equal variances and alpha levels of 5%. The analyses of the crossover portion of the study will be descriptive. Mean values will be plotted over time by arm. A formal crossover analysis will also be performed using Senn's linear modeling approach. |
Baseline to the end of four weeks and four weeks after cross-over
|
|
Change in arthralgias
Časové okno: Baseline to the end of four weeks and four weeks after cross-over
|
Measured by the Brief Pain Inventory for Aromatase Inhibitor Induced Arthralgia. Will be compared between arms using two-sample, two-sided t-tests assuming equal variances and alpha levels of 5%. The analyses of the crossover portion of the study will be descriptive. Mean values will be plotted over time by arm. A formal crossover analysis will also be performed using Senn's linear modeling approach. |
Baseline to the end of four weeks and four weeks after cross-over
|
|
Incidence of adverse events
Časové okno: Up to 30 days follow-up
|
Measured by the symptom experience diary. Will be compared between arms using two-sample, two-sided t-tests assuming equal variances and alpha levels of 5%. The analyses of the crossover portion of the study will be descriptive. Mean values will be plotted over time by arm. A formal crossover analysis will also be performed using Senn's linear modeling approach. |
Up to 30 days follow-up
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Vrchní vyšetřovatel: Stacy D. D'Andre, MD, Mayo Clinic in Rochester
Publikace a užitečné odkazy
Užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další identifikační čísla studie
- MC221002
- MC221002 (Jiný identifikátor: Mayo Clinic in Rochester)
- NCI-2023-06578 (Identifikátor registru: CTRP (Clinical Trials Reporting Program))
- 23-005266 (Jiný identifikátor: Mayo Clinic Institutional Review Board)
- MNCCTN032 (Jiný identifikátor: Minnesota Cancer Clinical Trials Network)
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
produkt vyrobený a vyvážený z USA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .